NCT06655376View on ClinicalTrials.gov

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients with Assist Device

PHASE4RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions
BleedingClot Blood
Interventions
DRUG

Aspirin

81-100 mg, oral

DRUG

Warfarin

Warfarin dose will be adjusted per patient for a goal INR 2-3. The individualized daily dose could range anywhere from 0.5-2 mg to 5-7 mg. Oral.

Trial Locations (1)

10032

RECRUITING

Columbia Irving Medical Center, New York

All Listed Sponsors
collaborator

Weill Medical College of Cornell University

OTHER

lead

Columbia University

OTHER

NCT06655376 - Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients with Assist Device | Biotech Hunter | Biotech Hunter